BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The proof of this concept has been provided by the remarkable antitumour activity of the small BCR (breakpoint cluster region)-ABL (Abelson) TK inhibitor imatinib in chronic myeloid leukaemia (CML) [11].